ArticleCancers2024

Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status.

Walid Shalata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.